Pharmacopeia

CWP-0105

FLUMAZENIL

Antidotes · Level 3

Core pharmacology

Class Group

Antidote

Indications Uses

1. as an aid to weaning and neurological assessment of ventilated patients who have received benzodiazepine sedation during intensive care
2. as part of the ‘wake-up’ test during scoliosis surgery
3. to reverse oversedation after endoscopy and
4. for diagnosis of, and assessment after, benzodiazepine overdose.

Chemical Pharmaceutics

imidazo-benzodiazepine

Presentation

clear, colourless solution containing 100 micrograms/ml of flumazenil

Main Action

Reversal of the actions of benzodiazepines

Mechanism of action

- competitive reversible antagonist at benzo site on GABA-A receptor
- only intrinsic effect is slight anticonvulsant effect

Onset Peak Duration

Onset: 30-60 sec
Duration: 15-140 min

need repeated doses to prevent relapse

Adverse Effects Toxicity

Minor:
- headache/visual symptoms/↑anxiety/N&V
Major:
- can cause dangerous convulsions if:
> benzo’s being taken for epilepsy
> mixed ODs with CNS stimulants & antidepressants
- seizures & severe withdrawal if taking benzo’s chronically

Absorption

Well absorbed orally (but significant first-pass hepatic metabolism, so not given by this route)

Protein binding

50%

Volume of distribution

0.9 L/kg

Metabolism

Liver
Inert metabolites: carboxylic acid and glucuronide

Excretion

Urine: 95%
Unchanged: 0.1%

Clearance

700-1100 ml/min

Half-life

53 mins

Special Points

improves the quality of emergence from
anaesthesia
reduces post-operative shivering

Route And Dose

IV
Bolus: Titrated in 100mcg increments
Total max adult dose: 1mg/5 mins, 3 mg/1 hr
Infusion: 100-400mcg/hr

question diagnosis if no response to repeated doses